Quinidine Sulfate

Quinidine Sulfate

Quinidine is a pharmaceutical component that acts as an antimalarial agent and an antiarrhythmic with the chemical constitution of cinchona alkaloid. It was initially approved in 2005 by the U.S. Food and Drug Administration for the treatment of malaria. It is sold under the brand name Nuedexta. Quinidine blocks the sodium and potential currents and prolongs cellular action potential. Quinidine sulfate is generally used to treat malaria, arrhythmia, sinus rhythm, and others. Quinidine sulfate is gaining prominence in the market owing to increasing cardiovascular disorders like arrhythmia, atrial fibrillation, and others, the surge in cases of malaria, inherited cardiovascular disorders, rising cases of obesity, and rising demand for oral drugs. For instance, a report published by the Centers for Disease Control and Prevention (CDC) in 2020, reported more than 219 million estimated cases of malaria were reported across the globe. Several factors, including a surge in the increasing awareness regarding cardiovascular diseases, increasing geriatric population, rise in consumption of tonic water, and increased investments from the government, public, and private sectors in healthcare departments are driving the growth of the market during the forecast period. According to the World Health Organization (WHO), the share of people aged above 60 will rise to 1.4 billion by 2030 while this share will increase to 2.1 billion by 2050 which would be more than double the share of the geriatric population in the year 2020 i.e., 1 billion.

The Quinidine Sulfate Market is expected to grow at a steady rate of around 7.1% owing to the increased prevalence of cardiovascular diseases globally due to prevalent unhealthy lifestyles which are directly responsible for obesity. For instance, as per the World Obesity Atlas 2022, estimations are such that 1 billion people worldwide, comprising one in five women and one in seven men will be suffering from obesity by the year 2030. Many new therapies are being introduced for treating these cardiovascular diseases including a combination of treatments, immunotherapy, and many more. Several other factors, such as rising genetic disorders, and increasing prevalence of hypertension among people are also driving this market of quinidine sulfate at a steady rate. For instance, in July 2023, the Centers for Disease Control and Prevention (CDC) reported that nearly half of adults had hypertension i.e., systolic blood pressure greater than 130 mmHg or a diastolic blood pressure greater than 80 mmHg in 2021.

• Based on the mode of administration, the market is bifurcated into oral and intravenous segments. The oral segment held the maximum share in the global market of quinidine sulfate in 2022. This segment dominated the market because of the rising demand for oral drugs among patients. Evidently, tablets are reported to be the most consumed solid dosage forms among all medication forms, because of their highly effective composition, and ease in consumption. The oral mode of drug administration is much more convenient and easy on pockets for the consumers which is boosting this segment’s growth. For instance, in December 2021, AstraZeneca proposed the idea of designing oral biologics using transient permeation enhancers which is expected to increase the half-life and allow improved stability against intestinal enzymes. Hence, due to the above reasons, the oral segment held a significant share of the market in 2022.
• Based on application, the market is categorized into malaria, arrhythmias, and others. The malaria segment is expected to hold a significant share of the market in the forecast period owing to the prevalent ill lifestyle of people, and rising temperature, rainfall, and humidity at higher altitudes. For instance, According to WHO's latest World Malaria Report, there were an estimated 241 million malaria cases and 627,000 malaria deaths worldwide in 2020. This represented about 14 million more cases in 2020 compared with 2019 and 69,000 more deaths. Apart from this, the surge in the usage of rapid diagnostic tests is also impelling the growth of this segment. Hence, the malaria category is expected to witness a higher CAGR during the forecast period amongst applications.
• For a better understanding of the market adoption of quinidine sulfate, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the global quinidine sulfate market in the year 2022 due to the increasing cardiovascular disorders, increasing malaria cases, and rising number of investments in developing effective therapeutics. Government organizations are initiating awareness programs to prevent the transmission of diseases like malaria and provide efficient care to patients. For instance, according to the American Journal of Managed Care pulmonary arterial hypertension is a rare disorder found in 15 to 50 persons per million within the U.S. and Europe. Also, according to the National Institute of Health, the mean prevalence of pulmonary arterial hypertension was 11.6 per million and the approximate incidence rate was 2.4 per million children per year in June 2020. Thus, North America held a significant share of the market in the year 2022.
• Some of the major players operating in the market include Bennet Pharmaceuticals Limited; Buchler GmbH; Cipla Inc.; Ipca Laboratories Ltd.; Larklab; Merck KGaA; PRISM INDUSTRIES PRIVATE LIMITED; Teva Pharmaceutical Industries Ltd.; VIVAN Life Sciences; Biophore.